Frontage (HKG:1521) recorded a net loss of around $900,000 in the first quarter of 2025, narrower than $1 million a year prior, a Monday Hong Kong bourse filing said.
Revenue for the biotech firm fell 11% year over year to $57.1 million in the three months from $63.9 million in the year-ago period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.